FDA Takes Actions to Secure Safety of Compounded Drugs

25 July 2018

BioPrarm International

The agency announced two research collaborations on bulk lists, updates to categories of bulk drug substances, and issued a warning about a bulk drug substance used in compounding.

On July 23, 2018, FDA announced efforts to protect public health by taking actions regarding drug compounding. The efforts are part of the implementation of the Drug Quality and Security Act and the agency’s 2018 Compounding Policy Priorities Plan. These new actions focus on bulk drug substances used in compounding.

“Addressing bulk drug substances used in compounding is an important priority for the agency,” said Anna Abram, Deputy Commissioner for FDA’s Policy, Planning, Legislation and Analysis, in a press statement. “The FDA seeks to implement the statutory requirements for bulk drug substances that can be used in compounding in a way that strikes a balance between preserving access to compounded drugs for patients who have a medical need for them while reducing the safety risks and protecting the FDA drug approval process. Input from stakeholders, including healthcare professionals, is critical to achieving this balance.”

As part of these efforts, the agency issued an alert on July 23 about the risk of cesium chloride, which is sometimes used by cancer patients, and announced it was moving the substance to category 2 under the agency’s interim policy on compounding with bulk drug substances under section 503A of the Food, Drug, and Cosmetic Act (FD&C). FDA stated that cesium chloride has not been proven safe or effective and possible serious adverse events associated with the use of the ingredient include abnormal heart rhythms, low potassium, seizures, fainting, cardiac arrest, and death.

According to FDA, category 2 bulk drug substances are substances nominated with sufficient supporting information to be evaluated by FDA for their eligibility to be included in the 503A bulks list but raise significant safety risks in compounding.  The agency intends to take regulatory action against compounders that use category 2 substances.

To develop a list of bulk drug substances compounded under section 503B of the FD&C, FDA will be working with the University of Maryland and Johns Hopkins University to gather and analyze information. The University of Maryland will work with medical specialty groups about the use of drug products in clinical practice. Johns Hopkins will study safety and effectiveness information on bulk drug substances used in compounding drugs for patients with autism.

The agency is also working to update the categories of substances that are subject to FDA’s interim policies on compounding bulk drug substances. Newly nominated or re-nominated substances with adequate support that do not present significant safety risk will be placed in category 1. Substances without adequate support will be placed in category 3 and will not be eligible for the interim policies.

“The FDA designed its interim policies to avoid unnecessary disruption to patient treatment. During this interim period, the FDA will continue to restrict compounding of essentially copies of FDA-approved products. If the FDA encounters such compounding during an inspection or otherwise, the agency intends to take action, such as issuing a warning letter or pursuing an injunction,” the agency stated.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more